Fibrin nanoconstructs: A novel processing method and their use as controlled delivery agents

Nanotechnology

Volumn 23, Issue 9, 2012, Pages

  Praveen, G ^a   Sreerekha, P R ^a   Menon, Deepthy ^a   Nair, Shantikumar V ^a   Chennazhi, Krishna Prasad ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDIC PH; CONTROLLED DELIVERY; DELIVERY ROUTES; DRUG ABSORPTION; DRUG ADMINISTRATION; DRUG ENCAPSULATION EFFICIENCY; DRUG RELEASE; GREEN CHEMISTRY; GROWTH FACTOR; HIGH STABILITY; HIGH YIELD SYNTHESIS; IMMUNOSUPPRESSIVE DRUGS; IN-VITRO; IN-VIVO; NANOCARRIERS; PARENTERAL ADMINISTRATION; PHYSIOLOGICAL PH; PORE DIAMETERS; PROCESSING METHOD; SELF-ASSEMBLED; SPHERICAL NANOPARTICLES; SPRAGUE-DAWLEY RATS; SUSTAINED RELEASE; TACROLIMUS; TEMPERATURE STABILITY; TISSUE ENGINEERING SCAFFOLD; WALL THICKNESS; WATER-IN-OIL;

NANOPARTICLES; NANOTUBES; PH; SCAFFOLDS (BIOLOGY); SURFACE ACTIVE AGENTS; TISSUE; ZETA POTENTIAL;

DRUG PRODUCTS;

FIBRIN; NANOCAPSULE; TACROLIMUS;

ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; METABOLIC CLEARANCE RATE; RAT; SPRAGUE DAWLEY RAT; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; DELAYED-ACTION PREPARATIONS; DIFFUSION; FIBRIN; METABOLIC CLEARANCE RATE; NANOCAPSULES; ORGAN SPECIFICITY; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS; TISSUE DISTRIBUTION;

EID: 84857282325     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/23/9/095102     Document Type: Article

References (32)

1. Klajnert B, Walach W, Bryszewska M, Dworak A and Shcharbin D 2006 Cytotoxicity, haematotoxicity and genotoxicity of high molecular mass arborescent polyoxyethylene polymers with polyglycidol-block-containing shells Cell Biol. Int. 30 24852 (Pubitemid 43276451)
2. Chan J M, Zhang L, Yuet K P, Liao G, Rhee J W, Langer R and Farokhzad O C 2009 PLGAlecithinPEG coreshell nanoparticles for controlled drug delivery Biomaterials 30 162734
3. Muzzarelli R A A 2010 Chitins and Chitosans as immunoadjuvants and non-allergenic drug carriers Mar. Drugs 8 292312
4. Janmey P A, Winer J P and Weisel J W 2009 Fibrin gels and their clinical and bioengineering applications J. R. Soc. Interface 6 110
5. Liu W, Jawerth L M, Sparks E A, Falvo M R, Hantgan R R, Superfine R, Lord S T and Guthold M 2006 Fibrin fibers have extraordinary extensibility and elasticity Science 313 634 (Pubitemid 44201134)
6. Lord S T 2007 Fibrinogen and fibrin: scaffold proteins in hemostasis Curr. Opin. Hematol. 14 23641 (Pubitemid 46597609)
7. Dresdale A, Rose E A, Jeevanandam V, Reemtsma K, Bowman F O and Malm J R 1985 Preparation of fibrin glue from single-donor fresh-frozen plasma Surgery 97 7504
8. Mol A, van Lieshout M I, Dam-de Veen C G, Neuenschwander S, Hoerstrup S P, Baaijens F P and Bouten C V 2005 Fibrin as a cell carrier in cardiovascular tissue engineering applications Biomaterials 26 311321 (Pubitemid 39647246)
9. Fang H, Peng S, Chen A, Li F, Ren K and Hu N 2002 Biocompatibility studies on fibrin glue cultured with bone marrow mesenchymal stem cells in vitro J. Huazhong Univ. Sci. Technol. Med. Sci. 24 2724
10. Ho W, Tawil B, Dunn J C and Wu B M 2006 The behavior of human mesenchymal stem cells in 3D fibrin clots: dependence on fibrinogen concentration and clot structure Tissue Eng. 12 158795 (Pubitemid 44174792)
11. Breen A, OBrien T and Pandit A 2009 Fibrin as a delivery system for therapeutic drugs and biomolecules Tissue Eng. B 15 20114
12. Zangi L, Levdansky L, Marx G and Gorodetsky R 2003 Isolation with fibrin microbeads of bone marrow-derived pluripotent cell lines Cell Transplant. 12 1934
13. Krishnan L K, Lal A V, Shankar P R U and Mohanty M 2003 Fibrinolysis inhibitors adversely affect remodeling of tissues sealed with fibrin glue Biomaterials 24 3217 (Pubitemid 35292576)
14. Rogers I and Casper R F 2004 Umbilical cord blood stem cells Best Pract. Res. Clin. Obstet. Gynaecol. 18 893908 (Pubitemid 40012026)
15. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G and Isner J M 1997 Isolation of putative progenitor endothelial cells for angiogenesis Science 275 9647 (Pubitemid 27087709)
16. Kim I, Ryu Y S, Kwak H J, Ahn S Y, Oh J L, Yancopoulos G D, Gale N W and Koh G Y 2002 EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells FASEB J. 16 11268
17. Kreilgaard M 2002 Influence of microemulsions on cutaneous drug delivery Adv. Drug Deliv. Rev. 54 S7798
18. Perka C, Arnold U, Spitzer R S and Lindenhayn K 2001 The use of fibrin beads for tissue engineering and sub sequential transplantation Tissue Eng. 7 35961 (Pubitemid 32574933)
19. Almqvist K F, Wang L, Wang J, Baeten D, Cornelissen M, Verdonk R, Veys E M and Verbruggen G 2001 Culture of chondrocytes in alginate surrounded by fibrin gel: characteristics of the cells over a period of eight weeks Ann. Rheum. Dis. 60 78190 (Pubitemid 32685880)
20. Mosesson M W 2005 Fibrinogen and fibrin structure and functions J. Thromb. Haemost. 3 1894904 (Pubitemid 41716577)
21. Leon T L, Elaissari A, Vinuesa J L O and Gonzalez D B 2007 Hofmeister effects on poly(NIPAM) microgel particles: macroscopic evidence of ion adsorption and changes in water structure ChemPhysChem 8 14856
22. Kanakis J and Dalas E 2000 The crystallization of vaterite on fibrin J. Cryst. Growth 219 27782
23. Meloan S N and Puchtler H 1988 On the chemistry of phosphotungstic acid-hematein: development of a rapidly ripening PTAH solution J. Histotechnol. 11 1537
24. Gurevich O, Vexler A, Marx G, Prigozhina T, Ledansky L, Slavin S, Shimeliovich I and Gorodetsky R 2002 Fibrin microbeads for isolating and growing bone marrow derived progenitor cells capable of forming bone tissue Tissue Eng. 8 66172 (Pubitemid 34857802)
25. Silvana M, Acosta L O C, Leiva L C, Ruiz R M, Aguirre M V and Teibler P 2004 Mice plasma fibrinogen consumption by thrombin-like enzyme present in rattlesnake venom from the North-East region of Argentina Medicina (B. Aires) 64 50917 (Pubitemid 40123602)
26. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour D C, Malaise J, Lison D, Squifflet J P and Wallemacq P 2004 The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients Pharmacogenetics 14 14754 (Pubitemid 38373108)
27. Turner E 1835 Substances which are neither acid nor oleaginous-fibrin Elements of ChemistryIncluding the Recent Discoveries and Doctrines of the Science (Philadelphia, PA: Desilver-Thomas and Co.) pp 5878
28. Nassar T, Rom A, Nyska A and Benita S 2009 Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug J. Control. Release 133 7784
29. Eastwood M, Porter R, Khan U, McGrouther G and Brown R 1996 Quantitative analysis of collagen gel contractile forces generated by dermal fibroblasts and the relationship to cell morphology J. Cell Physiol. 166 3342 (Pubitemid 26017776)
30. Shreiber D I, Enever P A and Tranquillo R T 2001 Effects of PDGF-BB on rat dermal fibroblast behavior in mechanically stressed and unstressed collagen and fibrin gels Exp. Cell Res. 266 15566 (Pubitemid 32989052)
31. Luo J C, Yamaguchi S, Shinkai A, Shitara K and Shibuya M 1998 Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors Cancer Res. 58 265260 (Pubitemid 28275440)
32. Myriam G, Inbal A, Yuval D, Esther B L, Ahuva I, Steffen Y, Stephano C, Limor L, Rinat A and Eli K 2006 VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells Cell 124 17589